This is a firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the University of Oxford, a non-profit, state-controlled institution of higher learning located in the United Kingdom. The contract, valued at $147,839.34, requires Oxford to conduct scientific research in Gueckedou, Guinea to collect and analyze biological samples of individuals potentially exposed or infected with the Marburg virus. The contract does not have a set-aside designation. Oxford has extensive experience collaborating on federally-funded projects across various research disciplines and regularly receives both contracts and grants from U.S. government agencies to support its mission of advancing knowledge and education through cutting-edge research and scholarship.
Generated 8/15/24, 9:46 AM